Emami Razavi Amirnader, Basati Gholam, Varshosaz Jaleh, Abdi Soheila
Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Acta Med Iran. 2013 Jul 13;51(6):365-71.
Myeloperoxidase (MPO) and paraoxonase-1 (PON1) are inflammatory and anti-inflammatory enzymes, respectively that have been involved in the pathogenesis of coronary artery disease (CAD). In this study we sought to evaluate the relations of MPO and PON1 with high density lipoprotein (HDL) mean size in patients with acute coronary syndrome (ACS). Collectively, 50 control subjects and 50 patients with ACS were participated in this study. MPO level and PON1 activity was determined using immunoassay and colorimetric methods, respectively. HDL mean size was determined by a dynamic light scattering methodology. Other clinical risk factors were also determined by standard methods. The MPO/PON1 ratio amount was significantly higher in patients with ACS (1.49±1.10) than in control subjects (0.21±0.14) (P<0.01). There was a significant correlation between MPO/PON1 ratio and HDL mean size in patients with ACS. Amount of the enzymes and their relations to HDL particle size in patients with ACS may play a part in the pathogenesis of ACS. Also, MPO/PON1 ratio may be a robust predictor of ACS.
髓过氧化物酶（MPO）和对氧磷酶-1（PON1）分别是炎症酶和抗炎酶，它们都参与了冠状动脉疾病（CAD）的发病机制。在本研究中，我们试图评估急性冠状动脉综合征（ACS）患者中MPO和PON1与高密度脂蛋白（HDL）平均大小之间的关系。共有50名对照受试者和50名ACS患者参与了本研究。分别使用免疫测定法和比色法测定MPO水平和PON1活性。通过动态光散射法测定HDL平均大小。其他临床危险因素也通过标准方法测定。ACS患者的MPO/PON1比值（1.49±1.10）显著高于对照受试者（0.21±0.14）（P<0.01）。ACS患者中MPO/PON1比值与HDL平均大小之间存在显著相关性。ACS患者中这些酶的含量及其与HDL颗粒大小的关系可能在ACS的发病机制中起作用。此外，MPO/PON1比值可能是ACS的一个有力预测指标。
